Sonoma Pharmaceuticals (SNOA) Fundamental Analysis: Revenue, Earnings & Valuation

0.38 / 10

Underperform

Fundamentals are underperforming. Asset‑MV and Profit‑MV show modest strength, while Revenue‑MV, Cash‑MV, ROA and profit margins are negative or weak. Overall financial ratios rank low, supporting a defensive outlook.

Analysis Checks(3/10)

Revenue-MV

Value0.71

Score0/3

Weight57.88%

1M Return-4.18%

ROA (%)

Value-24.32

Score1/3

Weight12.06%

1M Return-0.82%

Net cash flow from operating activities / Operating revenue (%)

Value-0.62

Score1/3

Weight19.02%

1M Return-1.35%

Profit-MV

Value0.66

Score2/3

Weight-54.66%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-24.32

Score1/3

Weight12.06%

1M Return-0.82%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight64.10%

1M Return-5.19%

Asset-MV

Value-0.50

Score3/3

Weight-83.04%

1M Return4.62%

Net profit / Total operating revenue (%)

Value-24.20

Score1/3

Weight12.29%

1M Return-0.84%

Cash-MV

Value0.02

Score1/3

Weight51.82%

1M Return-4.16%

Net profit / Total profit (%)

Value118.92

Score2/3

Weight8.47%

1M Return-0.54%

Is SNOA undervalued or overvalued?

SNOA scores 0.38/10 on fundamentals and holds a Premium valuation at present. Backed by its -66.15% ROE, -19.02% net margin, -1.09 P/E ratio, 1.07 P/B ratio, and 14.85% earnings growth, these metrics solidify its Underperform investment rating.